Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) EV/FCF
As of 5 November 2026, Smith & Nephew SNATS, Inc. (SNN) trades at a EV/FCF of 8.3×. Over the past ten years it has ranged from 7.1× (October 2026) to 58.9× (March 2015); the current reading is higher than 3% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 9.5× | (44.63%) |
| FY2024 | 17.1× | (67.04%) |
| FY2023 | 52.0× | 184.60% |
| FY2022 | 18.3× | 10.31% |
| FY2021 | 16.6× | 15.64% |
| FY2020 | 14.3× | 8.19% |
| FY2019 | 13.2× | 18.63% |
| FY2018 | 11.2× | 32.76% |
| FY2017 | 8.4× | (7.67%) |
| FY2016 | 9.1× | (43.44%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2023 | 30.2× | 68.02% |
| Dec 2022 | 18.0× | 45.59% |
| Jun 2022 | 12.4× | (26.01%) |
| Dec 2021 | 16.7× | 4.20% |
| 6 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNN Smith & Nephew SNATS, Inc. | 8.3× |
| GMED Globus Medical, Inc. compare | 14.9× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.8× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 29.5× |
| BRKR Bruker Corporation compare | 38.8× |
| PODD Insulet Corporation compare | 48.0× |
| TXG 10x Genomics compare | 58.9× |
| PEN Penumbra, Inc. compare | 59.8× |
| GKOS Glaukos Corporation compare | 360× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement